| |
Home >
Health and Fitness
>
Health and Fitness
>
Amerigel Is A Cost Effective Antimicrobial Wound Dressing
Amerigel Is A Cost Effective Antimicrobial Wound Dressing
In today’s world of increasing medical care costs, Amerx Health Care Corporation (“Amerx”), a subsidiary of Procyon Corporation (“Procyon”) (NASDAQ BB: PCYN), is pleased to announce the publication of a peer-reviewed scientific study authored by Jonathan Moore, DPM, MS, AAPWCA and Al Perkins, MD, PhD in the December 2010 issue of the Advances in Skin & Wound Care Journal (Lippincott Williams).
Clearwater,
FL,
United States
(pr4links.com)
06/03/2011
In today’s world of increasing medical care costs, Amerx Health Care Corporation (“Amerx”), a subsidiary of Procyon Corporation (“Procyon”) (NASDAQ BB: PCYN), is pleased to announce the publication of a peer-reviewed scientific study authored by Jonathan Moore, DPM, MS, AAPWCA and Al Perkins, MD, PhD in the December 2010 issue of the Advances in Skin & Wound Care Journal (Lippincott Williams).
The study, “Evaluating Antimicrobial Efficacy and Cost of Three Dressings Containing Silver Versus a Novel Antimicrobial Hydrogel Impregnated Gauze Dressing Containing Oakin®, an Oak Extract” examined the antimicrobial efficacy of four commonly used wound dressings ( http://www.amerigel.com/ ) and compared their treatment costs. Study results demonstrated that there were no substantial differences in the corrected zone of inhibition (CZOI) measurements between the silver wound care dressings and the less expensive Oakin® impregnated gauze wound care dressing (AmeriGel® Hydrogel Saturated Gauze Dressing). Despite the obvious limitations of this study, the results suggest the biggest differences between AmeriGel® and the antimicrobial silver dressings may be more in cost than in antimicrobial efficacy. The study found that the costs of treating 100 patients over a 7 week period with the more expensive silver products could range up to $80,000 compared to the AmeriGel® cost of $1,918 – a savings of 97.5%.
Per Dr. Moore, antimicrobial wound care dressings are well accepted and routinely used in the treatment of chronic and problematic wounds. While there are many differences in antimicrobial products on the market today, practitioners report few significant clinical differences between various common antimicrobial wound care dressings despite wide variations in cost. Dressings employ different active ingredients and different presentations of a particular active ingredient to protect the wound from bacterial colonization and promote wound repair. With so many topical antimicrobial dressings to choose from in the clinical setting, it was of prime interest to determine if there was a substantial difference between some of the more commonly used antimicrobial dressings with silver versus an antimicrobial wound dressing using Oakin®.
Amerx Health Care President, Justice Anderson, stated, “We have always believed the Amerigel® line of wound care products provide physicians and wound care professionals a cost-effective antimicrobial option. This study substantiates Amerigel’s ability to promote antimicrobial activity to infected wounds at a fraction of the cost.”
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: When used in this release, the words “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “believe,” and similar expressions, variations or the negative of these words, and any statement regarding possible or assumed future results of operations of our business, the markets for our products, anticipated expenditures, regulatory developments or competition, or other statements regarding matters that are not historical facts, are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. The reader should be aware that our actual results could differ materially from those contained in forward-looking statements. Our financial condition and the results of our operations will depend on a number of factors, including, but not limited to, the risk factors outlined in our Annual Report on 10-K for the year ended June 30, 2010, as filed wi
th the Securities and Exchange Commission on September 28, 2010. There may be other factors not mentioned above or included in our Securities and Exchange Commission filings that may cause actual results to differ materially from any forward-looking statement. The reader should not place undue reliance on any forward-looking statement. Neither the Company nor any of its corporate officers or key employees assumes any obligation to update any forward-looking statement as a result of new information, future event or development, except as required by securities laws.
###
About
The reader should not place undue reliance on any forward-looking statement. Neither the Company nor any of its corporate officers or key employees assumes any obligation to update any forward-looking statement as a result of new information, future event or development, except as required by securities laws.
|